Clinical and radiological effects of anakinra in patients with rheumatoid arthritis
|
|
- Augustine Edgar Berry
- 6 years ago
- Views:
Transcription
1 Rheumatology 2003;42(Suppl. 2):ii22 ii28 doi: /rheumatology/keg329, available online at Clinical and radiological effects of anakinra in patients with rheumatoid arthritis B. Bresnihan and M. Cobby 1 Interleukin-1 (IL-1) is a proinflammatory cytokine that plays a pivotal role in the pathophysiology of rheumatoid arthritis (RA). Inhibiting the activities of IL-1 at the receptor level with the recombinant human IL-1 receptor antagonist anakinra (Kineret ; Amgen Inc., Thousand Oaks, CA) is a new therapeutic option for the management of patients with RA. Randomized, placebo-controlled trials have demonstrated that anakinra, alone and in combination with methotrexate, improves the signs and symptoms of RA. Anakinra also produces improvements in patient functionality and health-related quality of life, as measured by the Health Assessment Questionnaire and the Nottingham Health Profile, and reduces the number of productivity days missed due to illness. Furthermore, an initial study indicates that anakinra retards the progression of radiographic joint damage. Such clinical findings suggest that anakinra is an important addition to the rheumatology treatment armamentarium. KEY WORDS: Anakinra, Efficacy, Functionality, Health-related quality of life, Interleukin-1 receptor antagonist, Radiographic progression, Rheumatoid arthritis. The proinflammatory cytokine interleukin-1 (IL-1) plays a pivotal role in the pathophysiology of rheumatoid arthritis (RA) [1]. In addition, IL-1 is the principal mediator of bone and cartilage destruction [2 5]. The IL-1 gene family includes IL-1α and IL-1β both agonist molecules produced principally by activated monocytes and macrophages and IL-1 receptor antagonist (IL-1Ra) [6, 7]. There are two distinct IL-1 receptors, designated type I (IL-1RI) and type II (IL-1RII) [7]. Binding of IL-1 to IL-1RI results in signal transduction and cell activation, producing many of the effects that are central to the pathogenesis of RA [7]. These include the up-regulation of small inflammatory mediators, such as cyclo-oxygenase type 2 and prostaglandin-e 2, from a number of cell types including macrophages and endothelial cells [6] and stimulation of matrix metalloproteinase release by fibroblast-like synoviocytes [8]. In contrast, binding of IL-1 to IL-1RII does not generateasignal;thus,thisreceptoractsasa decoy receptor that scavenges circulating IL-1α and IL-1β [9]. IL-1Ra is the third member of the IL-1 gene family and is also produced by activated monocytes and tissue macrophages [6, 7, 10]. When IL-1Ra binds to IL-1RI, it blocks the binding of IL-1α and IL-1β, thereby inhibiting signal transduction. In patients with RA, IL-1 is produced abundantly by synovial tissue mononuclear cells (Fig. 1). In a study of patients with early RA, it was observed that synovial tissue samples selected from areas adjacent to the cartilage pannus junction contained IL-1β-producing cells that occupied up to 58.6% (mean 14.9%) of the total tissue area [11]. In comparison, cells producing tumour necrosis factor alpha (TNFα) another proinflammatory cytokine occupied up to 11.7% (mean 6.7%) of the total tissue area. Moreover, IL-1α- and IL-1β-producing cells were demonstrated in the majority of patients with long-standing disease (duration of 6 29 yr), while fewer FIG. 1. Rheumatoid arthritis synovial tissue demonstrating numerous interleukin-1β-producing cells (dark staining). St Vincent s University Hospital, Dublin, Ireland and 1 Frenchay Hospital, Bristol, UK. Correspondence to: B. Bresnihan, Department of b.bresnihan@svcpc.ie Rheumatology, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland. ii British Society for Rheumatology
2 Clinical and radiological effects of anakinra ii23 patients were positive for TNFα. Further analyses of synovial explants indicated that there is an imbalance between IL-1 and IL-1Ra in the rheumatoid synovium, in favour of elevated IL-1 [12, 13]. Therefore, administration of exogenous IL-1ra to block binding of IL-1 to IL-1RI should translate into clinical benefits at all stages of RA. Anakinra (Kineret ; Amgen Inc., Thousand Oaks, CA) is a recombinant form of human IL-1Ra produced in an Escherichia coli expression system. This review will discuss the clinical and radiological effects of anakinra in patients with RA. TABLE 1. Randomized, placebo-controlled trials of anakinra Study Daily dosages of anakinra n a European Monotherapy Study [14] 0, 30, 75, 150 mg 472 Low-dose Monotherapy Study [15] 0, 2.5, 10, 30 mg 141 Methotrexate Combination 0, 0.04, 0.1, 0.4, 1.0, 419 Therapy Study [16] 2.0 mg/kg Confirmatory Efficacy Study [17] 0, 100 mg 501 Safety Study [18] 0, 100 mg 1399 Total 2932 a Number of patients who received at least one dose of the study drug. Clinical efficacy of anakinra Five randomized, placebo-controlled clinical trials of anakinra have been completed in a total of 2932 patients with RA: the European Monotherapy Study [14]; the Low-dose Monotherapy Study [15]; the Methotrexate (MTX) Combination Study [16]; the Confirmatory Efficacy Study [17]; and the Safety Study [18] (Table 1). The primary end-points of the first four studies were related to clinical efficacy, while primary outcome measures in the fifth study were safety-related. The European Monotherapy Study and the MTX Combination Study have both been published and, along with the Confirmatory Efficacy Study, demonstrate that anakinra improves the signs and symptoms of RA. A treatment effect was not observed in the Low-dose Monotherapy Study. The mean duration of RA across the five studies ranged from 3.5 to 10.8 yr. Mean baseline tender joint count ranged from 22.6 to 34.3 joints (out of a maximum of 68) and swollen joint count ranged from 18.3 to 26.1 joints (out of a maximum of 66). Mean baseline erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values were between 36.7 and 49.5 mm/h and 1.91 and 4.14 mg/dl, respectively. Up to 64.2% of patients were receiving corticosteroids and up to 87.0% were receiving non-steroidal anti-inflammatory drugs (NSAIDs) at baseline [15]. Improvements in the American College of Rheumatology response criteria In the European Monotherapy Study, patients (n = 472) were randomized to anakinra 30, 75, or 150 mg/day or placebo. At 24 weeks, 43% of patients receiving anakinra 150 mg/day achieved a 20% response according to the American College of Rheumatology (ACR) criteria (ACR20) [19], compared with 27% in the placebo group (P = 0.014) [14]. An early onset of action was seen in the active treatment groups, with a clinical effect observed as early as 2 weeks following initiation of therapy (Fig. 2) [15, 20]. Significantly greater improvements were observed at 24 weeks in each of the individual components of the ACR response criteria in the patients who were receiving the highest dosage of anakinra (150 mg/day) compared with those receiving placebo: the number of swollen and tender joints (P = FIG. 2. ACR20 response rate over time following treatment with anakinra administered as monotherapy, compared with placebo, in patients with RA (intent-to-treat with non-responder imputation) [15]. The early onset of action is demonstrated. and P = , respectively); physician and patient global assessments of disease activity (P = and P = 0.012, respectively); patient pain scores (P = 0.001); Health Assessment Questionnaire (HAQ) disease index (P = ); and both ESR and CRP values (P < and P = , respectively) [14]. A rapid onset of action was also observed with anakinra in the MTX Combination Study (Fig. 3) [16, 20]. Patients (n = 419) were randomized to anakinra at dosages ranging from 0.04 to 2.0 mg/kg/day. The overall magnitude of clinical response was assessed according to ACR20, ACR50 and ACR70 response at 12 and 24 weeks. At 12 weeks, anakinra 1.0 mg/kg/day was associated with an ACR20 response of 46%, an ACR50 response of 19%, and an ACR70 response of 5%. Corresponding response rates with anakinra 2.0 mg/kg/day were 38, 24 and 11%, compared with 19, 4, and 0% with placebo. The overall dose response was highly statistically significant (P = 0.001). At 24 weeks, there was also a significant dose response when the percentages of patients achieving an ACR20, ACR50 and ACR70 response were considered (P = 0.003). In the anakinra 1.0 mg/kg/day treatment group, the ACR20, ACR50 and ACR70 response rates were 42, 24 and 10%, respectively, compared with 23, 4 and 0% with placebo. Corresponding rates with anakinra 2.0 mg/kg/day were 35, 17 and 7%. Improvements in the individual components of the ACR response were seen most clearly in the
3 ii24 B. Bresnihan and M. Cobby FIG. 3. ACR20 response rate over time following treatment with anakinra administered in combination with MTX, compared with placebo plus MTX, in patients with RA (*P < 0.05, **P < 0.01, ***P = 0.001, vs placebo; intent-to-treat with non-responder imputation) [15, 16]. (Modified from Arthritis and Rheumatism) [16]. patient-reported outcomes, such as the patient pain score, HAQ score, and patient assessment of disease activity (Fig. 4A). When the physician-reported outcomes, such as the tender and swollen joint counts and the physician assessment of disease activity, were considered, the placebo responses were greater and the difference between the placebo and the optimal therapeutic responses were less than with the patient-reported measures (Fig. 4B). A sustained response to anakinra, defined as an ACR20 response at four or more of the six 4-weekly assessments and including either the 12- or 24-week assessment, was observed in 31% of patients who received anakinra 1.0 mg/kg/day (P = 0.039) and 35% of those who received anakinra 2.0 mg/kg/day (P = 0.013), compared with 15% of the placebo group. The Confirmatory Efficacy Study evaluated 501 patients who demonstrated an inadequate clinical response to therapeutic doses of MTX and were randomized to receive either placebo or anakinra at a fixed dosage of 100 mg/day in combination with maintenance MTX [17]. At 4 weeks, significantly more patients receiving anakinra had achieved an ACR20 response compared with those receiving placebo (P = 0.004). At 24 weeks, 38% of the treatment group achieved an ACR20 response, compared with 22% of the placebo group (P < 0.001). Consistent with the MTX Combination Study, improvements in the individual components of the ACR response were most evident in the patient-reported outcomes (data not shown) [21]. Effect of anakinra on measures of patient functionality Functional decline in RA is a consequence of both disease activity and structural joint damage and translates into impaired health-related quality of life and work disability [22, 23]. The effects of a therapeutic agent on measures of patient functionality are an important consideration when assessing treatment options for RA. In each of the three studies that evaluated therapeutically effective dosages of anakinra, clinically meaningful improvements in the HAQ scores (a reduction >0.22 from baseline) [24] were observed with active treatment (Fig. 5). In the European Monotherapy Study, patients receiving each of the anakinra dosages demonstrated reductions in HAQ scores at 24 weeks that were significantly better than the placebo group (P = 0.011, P = and P = with 30, 75 and 150 mg/day, respectively) [14]. Similarly, in the MTX Combination and the Confirmatory Efficacy studies, reductions in HAQ scores that were clinically meaningful and significantly better than placebo were observed in patients receiving anakinra 1.0 or 2.0 mg/kg/day (P = and P = , respectively) [16] or 100 mg/day (P = 0.017) [15]. The effects of anakinra on patient functionality and health-related quality of life were also assessed with the Nottingham Health Profile (NHP) in the European Monotherapy Study [25]. The NHP is a validated instrument that provides indications of patients perceived health problems, with a scale comprising 38 items that can be grouped into six subscales: mobility (five items), pain (eight items), sleep (five items), social isolation (five items), emotional reactions (nine items) and energy (three items) [26]. In the patients who received anakinra, there were significant improvements in the energy (P = 0.01), pain (P = 0.02), emotional reactions (P = 0.01) and physical mobility (P < 0.01) subscales at 24 weeks, compared with the placebo group. The Economic Resource Survey was employed in the European Monotherapy Study to evaluate patient and caregiver days of missed work or domestic activity in successive 4-week periods [27]. There were rapid gains overtimeinthenumberofdaysatworkordomestic activity in the patients treated with anakinra. Increases in productivity were dose-related, with a mean total of days gained over 24 weeks in patients receiving the highest dosage of anakinra compared with 3.55 days in the placebo group (P < 0.05). The mean total number of days gained across all three anakinra dosages was (P < 0.05 vs placebo). Moreover, an additional 14% of anakinra recipients did not miss any days of work or domestic activity over the course of the study. The corresponding decrease with placebo was only 6%. After completing the 24-week placebo-controlled phase of the European Monotherapy Study, patients were given the option of continuing therapy in a 24-week doubleblind extension phase. Patients receiving placebo during the first 24 weeks were randomized to one of the three anakinra dosages for the second 24 weeks, while patients originally randomized to anakinra continued to receive the same dosage during the extension phase. Patients who had received anakinra for the entire study period demonstrated a greater gain in productivity days during the second 24-week period compared with the first 24-week phase [28]. For example, the patients who received anakinra 150 mg/day for 48 weeks demonstrated a mean gain of days during the second 24-week period, compared with days during the first.
4 Clinical and radiological effects of anakinra ii25 FIG. 4. Improvements in individual ACR criteria components following treatment with anakinra administered in combination with MTX [15, 16]. Patient-reported outcomes are included in panel A; physician-reported outcomes are included in panel B (*P < 0.05, **P < 0.01, ***P < 0.001, vs placebo; intent-to-treat repeated mixed measures model). Patients who received anakinra at any dosage for 48 weeks demonstrated a mean gain of 2.82 productivity days per month during the second 24 weeks, compared with 2.04 days per month during the first. Prevention of structural damage with anakinra Joint damage occurs early in the course of RA with >50% of patients showing radiological erosions within the first 2 yr of disease onset [29]. The degree of joint damage
5 ii26 B. Bresnihan and M. Cobby FIG. 5. Improvements in the HAQ disease index over time from the European Monotherapy Study, MTX Combination Study and Confirmatory Efficacy Study [15]. Clinically relevant improvements (a reduction >0.22 from baseline) [24] were observed in all studies (*P < 0.05, **P < 0.01, ***P < 0.001, vs placebo). assessed by radiographic imaging represents a key outcome in RA and can be used to evaluate the effectiveness of an interventional therapy. Structural progression was selected as a secondary end-point in the first phase of the European Monotherapy Study and as a primary end-point for the extension phase of this study [14, 30]. Measuring radiographic disease progression The Larsen score [31] and Genant-modified Sharp score [32] were used to assess structural progression in the European Monotherapy Study [14, 30]. These scoring methods assess erosions and cartilage destruction in slightly different ways, but each can provide a single composite measure of overall joint damage for each subject after scoring individual joints of the hand and wrist. The Larsen scoring method has a relatively narrow reading scale, providing a conservative estimate of progression and combining joint space narrowing and joint erosion into a single global score. Films are read independently, with more emphasis placed on erosive damage. In contrast, the Genant-modified Sharp scoring method provides separate scores for joint space narrowing and erosion, which can then be combined to provide a total modified Sharp score. In this method, the examinations are read as a blinded set, i.e. with pre- and post-treatment radiographs available to the reader in blinded order. The modified Sharp scoring method has a comparatively extended scoring range and, therefore, potentially allows for more subtle radiographic changes to be detected and measured than the Larsen score. Effects of anakinra on radiographic progression In the European Monotherapy Study, radiographs were initially evaluated using the Larsen score alone. However, during recent years in Europe and for some time in North America, various modifications of the Sharp scoring method have been used to measure radiographic progression in different trials. For this reason, radiographs were reassessed using the Genant-modified Sharp score. When radiographs were scored with the Genantmodified Sharp method, anakinra significantly inhibited the progression of structural damage at all dosages tested (Fig. 6). At 24 weeks, there was a 47% reduction in the rate of progression for the combined treatment group compared with placebo (P = ) [30]. The pattern was similar when the radiographs were evaluated using erosion and joint space narrowing subscales of the Genant-modified Sharp score, with 38% (P = ) and 58% (P = ) reductions in progression observed, respectively, compared with placebo (data not shown). Introduction of anakinra in the extension phase of the European Monotherapy Study to patients initially randomized to placebo resulted in a slowing of disease progression at 48 weeks by up to half of that seen in the first phase [30]. Significantly less progression of structural damage was observed in patients who received anakinra for the entire 48-week treatment period compared with those receiving the active treatment in the second phase of the study only (P = and P = for the Genant-modified Sharp total score and erosion score, respectively). The sustained effects of anakinra on structural damage were further evident when the median change in
6 Clinical and radiological effects of anakinra ii27 FIG. 6. Least-squares mean change from baseline at 24 weeks in Genant-modified Sharp total score in the European Monotherapy Study [30]. Least squares mean change is the model-based change, where the model is change = baseline and treatment and country group (*P < 0.05, **P < 0.01, ***P < 0.001, vs placebo). Genant-modified Sharp total score over time was calculated. In patients who received anakinra for the entire 48-week study period, the median change in score was 0.6 during the first 24 weeks of treatment and <0.1 during the second 24 weeks (P < 0.001) [33]. In patients who received placebo for the first phase of the trial and who were then switched to anakinra during the second phase, the median change in score was 2.2 and 0.1 for the first and second phases, respectively (P < 0.001; Fig. 7). Patients who received active treatment during both phases of the trial experienced sustained benefit, in terms of structural progression. Analysis of the Genantmodified Sharp score subscales indicates that anakinra may exert its effects in dual fashion, with early and maintained protection of cartilage and an accelerated erosion benefit in the extension of the study. These findings suggest that anakinra has a role in the treatment of both early and established RA as it protects patients from the formation of erosions and preserves hyaline cartilage. Conclusions Anakinra, a recombinant human IL-1ra, specifically inhibits the proinflammatory and destructive pathophysiological effects of IL-1. Results from large efficacy studies indicate that treatment with anakinra results in significant improvements in the signs and symptoms of RA and has beneficial effects on functional status. The therapeutic effects occur early and are sustained throughout treatment. In addition, randomized clinical trials indicate that treatment with anakinra retards the FIG. 7. Change in Genant-modified Sharp score in radiographic progression in two consecutive 24-week periods in the European Monotherapy Study [33]. The top and bottom of the boxes represent the 75th and 25th percentiles, respectively. Means and medians are represented by + and grey lines, respectively. P-values are the result of Wilcoxon sign-rank test for equal median change from weeks 0 24 and weeks rate of structural joint damage in RA and is beneficial in preserving and protecting bone and cartilage. References 1. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38: Joosten LA, Helsen MMA, Saxne T, van De Loo FAJ, Heinegard D, van Den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collageninduced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999;163: van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(Suppl. 1):i Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43: Bresnihan B, Dayer J-M. IL-1Ra therapy in the treatment of rheumatoid arthritis. London: Martin Dunitz, Dinarello CA. The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343: Dayer J-M, Feige U, Edwards CK III, Burger D. Antiinterleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001;13: Dayer J-M, de Rochemonteix B, Burrus B, Demczuk S, Dinarello CA. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E 2 production by human synovial cells. J Clin Invest 1986;77: Colotta F, Dower SK, Sims JE, Mantovani A. The type II
7 ii28 B. Bresnihan and M. Cobby decoy receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994;15: Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16: Ulfgren A-K, Gröndal L, Lindblad S et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis 2000;59: Chomarat P, Vannier E, Dechanet J et al. Balance of IL-1Ra/IL-1β in RA synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154: Arend WP, Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2000;2: Bresnihan B, Alvaro-Gracia J-M, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41: US Food and Drug Administration (FDA). Kineret (anakinra) FDA briefing information. ohrms/dockets/ac/01/briefing/377961b1_01_amgen.pdf. 16. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46: Cohen SB, Moreland LW, Cush JJ et al. Kineret (anakinra) (recombinant interleukin-1 receptor antagonist): a large, placebo controlled efficacy trial of Kineret in patients with erosive rheumatoid arthritis disease. [Abstract] Ann Rheum Dis 2002;61(Suppl. 1): Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-methuil-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48: Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36: Miller DM, Ng E, Schiff MH, Cohen SB, Bresnihan B. Durability and rapidity of response for rheumatoid arthritis patients receiving therapy with anakinra (IL-1ra). [Abstract] Ann Rheum Dis 2001;60(Suppl. 1): Cohen S, Nakelsky S, Badamgarav E et al. The impact of Kineret (anakinra) therapy on patient-reported outcomes in rheumatoid arthritis. [Abstract] Ann Rheum Dis 2002;61(Suppl. 1): Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedfeld FC, Hazes JMW. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42: Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis development over 5 years. J Rheumatol 1995;22: Wells GA, Tugwell P, Kraag GR, Baker GRA, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient s perspective. J Rheumatol 1993;20: Emery P, Woolley JM, Chan WW. Improvement in health-related quality of life from anakinra therapy in patients with rheumatoid arthritis not using DMARDs. [Abstract] Ann Rheum Dis 2001;60(Suppl. 1): Houssien DA, McKenna SP, Scott DL. The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis. Br J Rheumatol 1997;36: Bresnihan B, Chan WW, Woolley JM. Anakinra increases days of work and domestic activity in patients with rheumatoid arthritis. [Abstract] Ann Rheum Dis 2001; 60(Suppl. 1): Bresnihan B, Chan WW, Woolley JM. Productivity improvement in patients with rheumatoid arthritis receiving anakinra treatment. [Abstract] Ann Rheum Dis 2001;61(Suppl. 1): Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;50: Jiang Y, Genant H, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43: Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;8: Genant HK, Jiang Y, Peterfy C, Lu Y, Redel J, Countryman P. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41: Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol 2002;29(Suppl. 65):
Bringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationNew Medicine Report. Anakinra Classification RED (Adopted by the CCG until review and further notice) Date of Last Revision 5 th July 2002
New Medicine Report Document Status Anakinra Classification RED (Adopted by the CCG until review and further notice) Post Suffolk D&TC Date of Last Revision 5 th July 2002 Approved Name Trade Name Manufacturer
More informationEfficacy of Anakinra in Bone: Comparison to Other Biologics
Advances In Therapy Volume 19 No. 1 January/February 2002 Efficacy of Anakinra in Bone: Comparison to Other Biologics Stephen A. Paget, M.D. Hospital for Special Surgery Department of Rheumatic Disease
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationThe role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Rheumatology 2004;43(Suppl. 3):iii2 iii9 The role of interleukin-1 in the pathogenesis of rheumatoid arthritis J. Kay and L. Calabrese 1 doi:10.1093/rheumatology/keh201 A significant body of experimental
More informationAnakinra in rheumatoid arthritis
Anakinra in rheumatoid arthritis Barry Bresnihan Department of Rheumatology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland Introduction Interleukin-l (IL-l) plays a central role in the
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationThe impact of new biologicals in the treatment of rheumatoid arthritis
Rheumatology 2004;43(Suppl. 3):iii17 iii23 The impact of new biologicals in the treatment of rheumatoid arthritis doi:10.1093/rheumatology/keh203 The past decade has seen a shift in the paradigm for RA
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More informationHigh serum and synovial fluid granulocyte colony stimulating factor (G-CSF) concentrations in patients with rheumatoid arthritis
Hypothalamus-pituitary-adrenocortical and -gonadal axis in RA / M. Cutolo The role of different fixatives for ANCA testing / EDITORIAL A. Radice et al. High serum and synovial fluid granulocyte colony
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationBRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1
BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended
More informationStructural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde
Structural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde University Hospital Maastricht, Maastricht, The Netherlands; and Limburg University Center, Diepenbeek,
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationFDA Perspective on Disease Modification in Schizophrenia
FDA Perspective on Disease Modification in Schizophrenia Robert Levin, M.D. Clinical Team Leader Division of Psychiatry Products Food and Drug Administration Goals and Expectations Develop treatments that
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationPotential Role of Sphingosine 1-Phosphate in the. Pathogenesis of Rheumatoid Arthritis
Potential Role of Sphingosine 1-Phosphate in the Pathogenesis of Rheumatoid Arthritis COMMENTARY for Zhao, C., Fernandes, M.J., Turgeon, M., Tancrede, S., Di Battista, J., Poubelle, P.E. and Bourgoin,
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationV. P. K. Nell 1, K. P. Machold 1, G. Eberl 2, T. A. Stamm 1, M. Uffmann 3 and J. S. Smolen 1,2
Rheumatology 2004;43:906 914 Advance Access publication 27 April 2004 Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationG. Karanikolas 1, D. Charalambopoulos 1, G. Vaiopoulos 2, A. Andrianakos 3, A. Rapti 4, D. Karras 5, E. Kaskani 6 and P. P. Sfikakis 1.
Rheumatology 2008;47:1384 1388 Advance Access publication 28 June 2008 doi:10.1093/rheumatology/ken223 Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide,
More informationPROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1995;34:1146-1150 PROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS L. PAEVDELA, T. PALOSUO,* M. LEIRISALO-REPO,t T. HELVE
More information(For National Authority Use Only) Page:
2.0 Synopsis AbbVie Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: HUMIRA 40 mg/0.8 ml for subcutaneous injection Page: (For National Authority Use Only) Name of Active
More informationof 0.20) and Health assessment questionnaire disability index (HAQ-DI) (r partial
IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of
More informationTreatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination With Methotrexate
ARTHRITIS & RHEUMATISM Vol. 46, No. 3, March 2002, pp 614 624 DOI 10.1002/art.10141 2002, American College of Rheumatology Treatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationPRODUCT INFORMATION. ORENCIA (abatacept) (LYOPHILIZED POWDER FOR IV INFUSION) (SOLUTION FOR SUBCUTANEOUS ADMINISTRATION)
PRODUCT INFORMATION ORENCIA (abatacept) (LYOPHILIZED POWDER FOR IV INFUSION) (SOLUTION FOR SUBCUTANEOUS ADMINISTRATION) NAME OF THE MEDICINE ORENCIA (abatacept (rch)) ORENCIA (abatacept (rch)). Abatacept
More informationAbatacept: first T cell co-stimulation modulator for severe active RA
Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION TOFACITINIB (Xeljanz Pfizer Canada Inc.) Indication: Rheumatoid Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be listed, in combination
More informationReport on New Patented Drugs - Orencia
Report on New Patented Drugs - Orencia Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationDiscussion Areas. Patient Reported Outcome Measures in Clinical Practice and Research Arthritis as an Exemplar
Patient Reported Outcome s in Clinical Practice and Research Arthritis as an Exemplar Leigh F. Callahan, PhD Program on Health Outcomes Seminar March 4, 25 Traditionally, clinical measures of biologic
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationMAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt.
MAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt. AUTOIMMUNE DISEASE RA SLE VASCULITIS RELAPSING POLYCHONDRITIS SS DM/PM SJOGREN S SYNDROME RHEUMATOID ARTHRITIS Classically immune mediated
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationG. Poór for the Leflunomide Multinational Study Group and V. Strand 1
Rheumatology 2004;43:744 749 Advance Access publication 16 March 2004 Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind,
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKey Words: Rheumatoid Arthritis, etanercept, post-marketing study, comparative study
CLINICAL DATA GAP BETWEEN PHASE III CLINICAL TRIALS (PRE-MARKETING) AND PHASE IV (POST-MARKETING) STUDIES: EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS Pendar Farahani 1,3, Mitchell Levine 1,2, Kathryn
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationB cells: a fundamental role in the pathogenesis of rheumatoid arthritis?
Rheumatology 2005;44(Suppl. 2):ii3 ii7 B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? doi:10.1093/rheumatology/keh616 The role of T cells in the pathogenesis of RA is well established,
More informationMeta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis
Jansen et al. BMC Musculoskeletal Disorders (2016) 17:348 DOI 10.1186/s12891-016-1195-4 RESEARCH ARTICLE Open Access Meta-analysis of long-term joint structural deterioration in minimally treated patients
More informationBiologics in Rheumatoid Arthritis
Update Article Biologics in Rheumatoid Arthritis P K Sharma*, D Hota**, P Pandhi*** Abstract Rheumatoid arthritis (RA) is a chronic progressive disease of the joints associated with significant morbidity,
More informationReview Article Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
Clinical and Developmental Immunology Volume 2013, Article ID 310628, 16 pages http://dx.doi.org/10.1155/2013/310628 Review Article Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect NAME OF MEDICINE SIMPONI Solution for Injection in a pre-filled syringe
More informationReceived: 9 Oct 2002 Revisions requested: 20 Nov 2002 Revisions received: 12 Mar 2003 Accepted: 19 Mar 2003 Published: 29 Apr 2003
Research article Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept Meliha Crnkic 1, Bengt Månsson 1,2, Lotta Larsson 1, Pierre
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationKineret (anakinra) When Policy Topic is covered Kineret (anakinra) requires prior authorization through the pharmacy services area.
Kineret (anakinra) Policy Number: 5.01.622 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Kineret (anakinra)
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationSerum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis
Rheumatology 2003;42:83 88 doi:10.1093/rheumatology/keg037, available online at www.rheumatology.oupjournals.org Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis M.J.Green,A.K.S.Gough,J.Devlin,J.Smith,P.Astin,
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationI n the past, analgesics and nonsteroidal
Rituximab in advanced rheumatoid arthritis Michael Guida BSc, MA Rheumatoid arthritis (RA) continues to have a major impact on public health. Costs to the individual and to the NHS are high, and treatment
More informationRheumatoid Arthritis Program: Top-line Phase 2 Results
Rheumatoid Arthritis Program: Top-line Phase 2 Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future
More informationK. Laas 1, R. Peltomaa 1, K. Puolakka 2, H. Kautiainen 3, M. Leirisalo-Repo 1
Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H.
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More informationScintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia Rheumatica
The Open General and Internal Medicine Journal, 29, 3, 53-57 53 Open Access Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia
More informationDrug Class Review on Targeted Immune Modulators
Drug Class Review on Targeted Immune Modulators Final Report Update 1 Evidence Tables January 2007 Original Report Date: December 2005 A literature scan of this topic is done periodically The purpose of
More information